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For decades, metabolic syndrome and locomotive syndrome have become major medical and social problems in developed 
and developing countries. Among them, obesity seems to be the fundamental cause of those illnesses. Several standard 
treatments are used for obesity, such as diet, exercise, and behavioral therapies so far. Intervention for the lifestyles would be 
indispensable. Some surgery methods may be performed when the case is estimated to be necessary [1].  
 
However, pharmacotherapy for obesity has been more frequent for long. From historical point of view, several kinds of 
agents for obesity have been developed [2]. Among them, some agents have been used until now, which are Phentermine, 
Mazindol, Orlistat, Phentermine/Topiramate, Naltrexone/Bupropion and Liraglutide from 1959 to present [3]. In this article, 
recent perspectives and topics concerning some medical agents for obesity would be described with up-to-date medical 
information.  
Abstract 
Obesity has been crucial diseases. Several agents have been used including Phentermine, Mazindol, Orlistat, 
Phentermine/Topiramate, Naltrexone/Bupropion and Liraglutide from 1959 to present. Glucagon like peptide-1receptor 
agonists (GLP-1RAs) has been used for type 2 diabetes mellitus (T2DM). As GLP-1RA, liraglutide is given 0.9 mg/day for 
T2DM, and 3.0 mg/day for obesity. Similary, semaglutide is given 1.0 mg/week for T2DM and 2.4 mg/week for obesity. 
Semaglutide brought 14.9% weight reduction for 68 weeks. There is a novel combination of GLP-1RA and glucose-
dependent insulinotropic polypeptide (GIP) for treating obesity, which achieved at least 10% weight reduction in 6-39% of 
cases for 26 weeks. 
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As regards to anti-obesity medicine, there are some agents that are particularly expected in recent years [4]. They are 
glucagon like peptide-1receptor agonists (GLP-1RAs), which were expected to have an insulin secretagogue action from 
pancreatic β cells as an incretin-related drug [5]. When liraglutide is provided, starting dose is 0.3mg/day, followed by usual 
maintenance dose 0.9 mg/day and maximum dose 1.8 mg/day. After lots of clinical experiences of liraglutide, the effect of 
suppressing appetite was widely known, that is via GLP-1 receptors expressed in the central nervous system such as the 
hypothalamus [6]. As a result, liraglutide (Saxenda R) has been approved in the United States as an anti-obesity drug with a 
maximum dose of 3.0 mg and has already been launched [7].  
 
Similarly, there has been semaglutide as one of GLP-1RAs for diabetes. It starts with a 0.25 mg injection once per week, 
maintains usually at 0.5 mg/week, and increases up to 1.0 mg/week when needed. As to the indication for obesity, clinical 
study of semaglutide has been conducted with a maximum dose of 2.4 mg/week. In particular, the effect of weight reduction 
was observed 14.9% for 68-week period. Simultaneously, the control group showed 2.4% reduction [8]. Then, the difference 
is calculated to be 12.5%. Consequently, it is expected that this will be applied in the actual practice for the near future [9].  
 
LY3298176 has been a novel combination of GLP-1RA and glucose-dependent insulinotropic polypeptide (GIP) [10]. It was 
developed for the purpose of treatment of T2DM. The effect and safety of these agents were studied for poor controlled 
T2DM. The study included 316 cases for 6 treatment groups, which are LY3298176 (1, 5, 10, or 15 mg), dulaglutide (1.5 
mg), or placebo for 26 weeks. As a result, LY3298176 showed HbA1c reduction as -1.06%, -1.73%, -1.89%, -1.94% for 1 
mg, 5 mg, 10 mg, 15 mg, respectively. Furthermore, it showed compared difference data to dulaglutide of HbA1c as -0.15%, 
-0.52%, -0.67%, -0.73%, for 1 mg, 5 mg, 10 mg, 15 mg, respectively. Regarding weight changes, 14%-71% of cases in group 
LY3298176 achieved at least 5% reduction (vs 22% with dulaglutide, 0% with placebo) and 6%-39% achieved at least 10% 
reduction (vs 9% with dulaglutide, 0% with placebo). Consequently, dual GIP and GLP-1RA (LY3298176) showed 
significantly higher effect for glucose variability and weight reduction than dulaglutide. It was associated with an acceptable 
safety and tolerability profile [11]. This agent will develop a new therapeutic option for T2DM.  
 
As options for weight control, two agents were known. They are GLP-1RA, semaglutide and a long-acting amylin analogue, 
Cagrilintide [12]. The study was conducted for the purpose of combined administration of these agents in the light of 
pharmacokinetics, tolerability and safety. The methods included the assignment of subcutaneous cagrilintide (6 different 
doses: 0.16, 0.30, 0.60, 1.2, 2.4, 4.5 mg) once-weekly for 20 weeks, associated with semaglutide 2.4 mg. As a result, the 
mean weight reduction was -7.4% for combined semaglutide 2.4 mg and cagrilintide 4.5 mg. This concomitant therapy 
showed safety and toleration. Future trials and research will be expected for the combination of these agents.  
 
What kind of mechanism does GLP-1RA work in the light of neurology and gastroenterology? After subcutaneous 
administration, GLP-1RA is thought to reach the central nervous system (CNS) directly or act on the appetite center of the 
hypothalamus via the vagal afferents [13]. It is known that it suppresses appetite and increases energy consumption, and also 
acts on gastrointestinal motility such as the medulla oblongata terminal area and the center of nausea and vomiting. Among 
these, it is not clarified the extent to which the action in the medulla oblongata terminal area has anti-obesity effect. As a 
matter of fact, however, the important point is how much the reverse effects related to the gastrointestinal tract can be 
reduced. Consequently, GLP-1RA can bring weight reduction and influence neural activities of energy expenditure, reward 
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and food intake [13]. GLP-1RA is known to induce dietary patterns that repel high-fat diets [14]. From this point of view, 
progress in research is expected for the future changes in dietary preferences.  
 
As described above, the development of anti-obesity agents has been currently a large boom worldwide for targeting 
gastrointestinal hormones and their receptors. Furthermore, glucagon [15], cholecystokinin (CCK) [16], peptide YY (PYY) 
[17], growth differentiation factor 15 (GDF-15) [18], and other agents can enhance the signal of appetite-suppressing 
hormones. Research developments are found concerning the hormone “ghrelin” that can promote appetite. One is the agent 
that reduce the action of ghrelin, and another is the agent that enhance the action of ghrelin inhibitor liver-expressed 
antimicrobial peptide 2 (LEAP-2) [19].  
 
In summary, there has been a history of hardship for treating obesity for long [2,3]. Starting the injectable treatment of GLP-
1RA in clinical practice, there is no doubt that pharmacotherapy in this area has entered a new era. As this agent becomes one 
of the triggers, international basic, clinical, and translational medical research will be brought together and developed. 
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